Cutaneous lymphoid perivascular reaction with atypical CD30+ T cells in a patient with multiple myeloma treated with bortezomib

Clinical and Experimental Dermatology

Volumn 34, Issue 8, 2009, Pages

  Dehesa, L ^a   Bastida, J ^a   Limeres Gonzalez M ^a   Campos Adsuar, C ^a   Gomez Duaso J ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD30 ANTIGEN;

AGED; CASE REPORT; CUTANEOUS LYMPHOID PERIVASCULAR REACTION; CUTANEOUS LYMPHOID PERIVASCULAR RECTION; HISTOPATHOLOGY; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN MANIFESTATION; T LYMPHOCYTE;

AGED; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG ERUPTIONS; HUMANS; MALE; MULTIPLE MYELOMA; PYRAZINES; T-LYMPHOCYTE SUBSETS;

EID: 72549098978     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03716.x     Document Type: Letter

References (5)

1. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 2006 57 : 33 47. (Pubitemid 43261977)
2. Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol 2006 55 : 897 900.
3. Gerecitano J, Goy A, Wright J et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006 134 : 391 398.
4. Quian YW, Siegel D, Bhattacharyya P. Multiple skin lesions in a patient with multiple myeloma. CD30-positive cutaneous large cell lymphoproliferative disorder. Arch Pathol Lab Med 2006 13 : 41 3.
5. Sangueza OP, Cohen DE, Calciano A et al. Mycosis fungoides induced by phenytoin. Eur J Dermatol 1993 3 : 474 477.